TRVI
Price:
$2.95
Market Cap:
$214.15M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.[Read more]
Industry
Biotechnology
IPO Date
2019-05-07
Stock Exchange
NASDAQ
Ticker
TRVI
According to Trevi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.37. This represents a change of 18.53% compared to the average of -6.22 of the last 4 quarters.
The mean historical PE Ratio of Trevi Therapeutics, Inc. over the last ten years is -4.10. The current -7.37 PE Ratio has changed 17.87% with respect to the historical average. Over the past ten years (40 quarters), TRVI's PE Ratio was at its highest in in the December 2017 quarter at -0.25. The PE Ratio was at its lowest in in the December 2022 quarter at -8.60.
Average
-4.10
Median
-3.86
Minimum
-11.48
Maximum
-0.53
Discovering the peaks and valleys of Trevi Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 711.71%
Maximum Annual PE Ratio = -0.53
Minimum Annual Increase = -60.54%
Minimum Annual PE Ratio = -11.48
Year | PE Ratio | Change |
---|---|---|
2023 | -4.57 | 6.85% |
2022 | -4.27 | 711.71% |
2021 | -0.53 | -60.54% |
2020 | -1.33 | -21.03% |
2019 | -1.69 | -50.93% |
2018 | -3.44 | -37.41% |
2017 | -5.50 | -52.11% |
The current PE Ratio of Trevi Therapeutics, Inc. (TRVI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-3.12
5-year avg
-2.48
10-year avg
-4.10
Trevi Therapeutics, Inc.’s PE Ratio is less than aTyr Pharma, Inc. (-2.33), less than Cue Biopharma, Inc. (-0.63), less than AN2 Therapeutics, Inc. (-0.47), less than BioAtla, Inc. (-0.80), less than Spero Therapeutics, Inc. (4.06), less than Bolt Biotherapeutics, Inc. (-0.37), less than Coherus BioSciences, Inc. (-4.85), greater than Gracell Biotechnologies Inc. (-12.26), less than Neoleukin Therapeutics, Inc. (-0.98), less than Foghorn Therapeutics Inc. (-4.49), less than C4 Therapeutics, Inc. (-3.44), less than Cyteir Therapeutics, Inc. (-3.52), less than Prelude Therapeutics Incorporated (-2.83), less than Rezolute, Inc. (-3.80), less than Lyra Therapeutics, Inc. (-0.18), less than SQZ Biotechnologies Company (-3.78), less than Protara Therapeutics, Inc. (-0.97), less than TRACON Pharmaceuticals, Inc. (0.03), less than Seer, Inc. (-1.29), less than ORIC Pharmaceuticals, Inc. (-6.13), less than Anebulo Pharmaceuticals, Inc. (-4.99), less than Cullinan Oncology, Inc. (-6.96),
Company | PE Ratio | Market cap |
---|---|---|
-2.33 | $131.12M | |
-0.63 | $28.70M | |
-0.47 | $30.44M | |
-0.80 | $84.10M | |
4.06 | $71.07M | |
-0.37 | $24.78M | |
-4.85 | $142.86M | |
-12.26 | $989.87M | |
-0.98 | $8.20M | |
-4.49 | $416.63M | |
-3.44 | $374.42M | |
-3.52 | $108.71M | |
-2.83 | $266.87M | |
-3.80 | $240.80M | |
-0.18 | $17.85M | |
-3.78 | $12.83M | |
-0.97 | $38.27M | |
0.03 | $194.57K | |
-1.29 | $100.74M | |
-6.13 | $680.74M | |
-4.99 | $46.68M | |
-6.96 | $1.04B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Trevi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Trevi Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Trevi Therapeutics, Inc. (TRVI)?
What is the highest PE Ratio for Trevi Therapeutics, Inc. (TRVI)?
What is the 3-year average PE Ratio for Trevi Therapeutics, Inc. (TRVI)?
What is the 5-year average PE Ratio for Trevi Therapeutics, Inc. (TRVI)?
How does the current PE Ratio for Trevi Therapeutics, Inc. (TRVI) compare to its historical average?